Morphine extended release - Egalet

Drug Profile

Morphine extended release - Egalet

Alternative Names: ARYMO; ARYMO ER; EG-P113; EG-PO66 Morphine; Egalet Morphine; Egalet-001; Morphine sulfate - Egalet

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Egalet
  • Class Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 15 Dec 2017 Egalet expects final approval for label update for pain management in October 2018
  • 15 Dec 2017 FDA grants tentative approval for a label update for morphine extended release for pain management in USA
  • 11 Jun 2017 The label for morphine extended release contains boxed warning
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top